Loading stock data…
PRTC
$17.42+0.17 (+0.99%)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PureTech Health PLC in the Healthcare sector is trading at $17.42. The stock is currently 13% below its 52-week high of $19.92, remaining 1.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$17.42
Potential Downside
0%
Whystock Fair Value$17.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-20...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
6,761
Recent News
Seaport Therapeutics stock pops 17% on Nasdaq debut
The Boston-based biotech sold more stock than originally planned at $18 a share, giving it a market value of $1.1 billion
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9...
PureTech Health H2 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) used its annual results call to outline a refined operating strategy centered on a leaner corporate structure, earlier formation of “founded entities,” and an increased emphasis on returning capital to shareholders when significant inflows occur. Chief Executive Office
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
Key Insights Significantly high institutional ownership implies PureTech Health's stock price is sensitive to their...
PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary Fibrosis
PureTech Health (PRTC) said Monday that it completed the end-of-phase 2 meeting with the US Food and